According to a market report by Lucintel, the future of the global artemisinin combination therapy market looks promising with opportunities in the hospital, clinic markets. The global artemisinin combination therapy market is expected to grow with a CAGR of 8.2% from 2025 to 2031. The major drivers for this market are its demonstrated effectiveness in quickly eliminating parasitemia, alleviating symptoms enhances treatment success rates, and prevent the emergence of drug-resistant malaria strains.
A more than 150-page report to understand trends, opportunity and forecast in artemisinin combination therapy market to 2031 by type (artemether+lumefantrine, artesunate+amodiaquine, dihydroartemisinin+piperaquine, artesunate+mefloquine, artesunate+sulfadoxine-pyrimethamine, pyronaridine-artesunate, and others), application (hospital, clinic, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the type category, artemether+lumefantrine is expected to witness the highest growth over the forecast period due to its superior effectiveness and safety in treating uncomplicated malaria.
Within the application category, clinic is expected to witness the higher growth due to treatments are commonly administered in clinics, especially in malaria-endemic regions.
Download sample by clicking on artemisinin combination therapy market
In terms of region, North America will remain the largest region over the forecast period due to the rising number of imported malaria cases and the need for effective treatment options.
KPC Pharmaceuticals, Sanofi, Desano Holdings, Mylan, Novartis are the major suppliers in the artemisinin combination therapy market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected] To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056
Explore Our Latest Publications
Digital Photography Market
E-learning Service Market
Emulsifiable Metalworking Fluid Market
Eucommia Leaf Extract Market
Germanium Sesquioxide Market